<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-8123</journal-id>
<journal-title><![CDATA[Revista Colombiana de Reumatología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Colomb.Reumatol.]]></abbrev-journal-title>
<issn>0121-8123</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Reumatología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-81232022000400239</article-id>
<article-id pub-id-type="doi">10.1016/j.rcreu.2021.03.014</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Biological therapy in rheumatoid arthritis: A review of adverse reactions]]></article-title>
<article-title xml:lang="es"><![CDATA[Terapia biológica en artritis reumatoidea: una revisión de reacciones adversas]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Orozco]]></surname>
<given-names><![CDATA[Víctor Hugo Arturo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Burgos García]]></surname>
<given-names><![CDATA[Mónica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Girón]]></surname>
<given-names><![CDATA[Luz Nelly]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pacheco]]></surname>
<given-names><![CDATA[Robinson]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Coomeva EPS  ]]></institution>
<addr-line><![CDATA[Cali ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Santiago de Cali Facultad de Salud Departamento de Ciencias Clínicas]]></institution>
<addr-line><![CDATA[Cali ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Libre Facultad de Ciencias de la Salud ]]></institution>
<addr-line><![CDATA[Cali ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>29</volume>
<numero>4</numero>
<fpage>239</fpage>
<lpage>248</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-81232022000400239&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-81232022000400239&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-81232022000400239&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  The relationship between adverse events and the application of biological drugs in patients with a diagnosis of rheumatoid arthritis has been documented worldwide, but with little evidence of the situation in Colombia. If adverse events and/or drug reactions with relevant clinical findings in health because of this therapeutic treatment affect the patient's quality of life and influence health indicators at the national level and system resources, it is important to assess their impact.  Objectives:  To determine the frequency of adverse events and/or adverse reactions related to the use of biological drugs in a cohort of patients diagnosed with rheumatoid arthritis from a national insurer, in the period from 2000 to 2019.  Methodology:  A descriptive, cross-sectional, and retrospective study with analytical scope was carried out in patients diagnosed with rheumatoid arthritis, on biological therapy, under a nationwide insurer, with records in their medical records from 2000 to 2019. Results: 252 clinical records of users with a rheumatoid arthritis diagnosis and biological therapy were analysed; 62.7% had at least one adverse reaction; nine drugs were evaluated in this study: Tocilizumab, Etanercept, Adalimumab, Abatacept, Certolizumab, Golimumab, Infliximab, Rituximab, and Tofacitinib. Tofacitinib was included in this study at the request of the insurer providing the information.  Conclusions:  Adverse reactions with biological therapy in patients with rheumatoid arthritis are frequent and were severe in 27.3%. This is a situation previously unknown in Colombia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La relación entre eventos adversos y aplicación de medicamentos biológicos en pacientes con diagnóstico de artritis reumatoide ha sido documentada a escala mundial, pero con escasa evidencia en Colombia. Si se asume que los eventos adversos o reacciones medicamentosas con hallazgos clínicos relevantes en la salud, como consecuencia de este tratamiento terapéutico, recaen sobre la calidad de vida del paciente e influyen en los indicadores de salud a escala nacional y en los recursos del sistema, se hace importante evaluar su impacto.  Objetivos:  Determinar la frecuencia de eventos adversos o reacciones adversas relacionados con el uso de medicamentos biológicos en una cohorte de pacientes con diagnóstico de artritis reumatoide de una aseguradora nacional, en el periodo comprendido entre los arios 2000 y 2019.  Metodología:  Se realizó un estudio descriptivo, transversal y retrospectivo, con alcance analítico, en pacientes diagnosticados de artritis reumatoide, con terapia biológica, en una aseguradora a escala nacional, con registros en historias clínicas del año 2000 al 2019.  Resultados:  Se analizaron 252 registros clínicos de usuarios con diagnóstico de artritis reumatoide y terapia biológica. El 62,7% presentó al menos una reacción adversa y se evaluaron 9 fármacos: tocilizumab, etanercept, adalimumab, abatacept, certolizumab, golimumab, infliximab, rituximab y tofacitinib. Este último es un fármaco incluido en este estudio por solicitud de la aseguradora fuente de la información.  Conclusiones:  En la terapia biológica de pacientes con artritis reumatoide las reacciones adversas son frecuentes, y en un 27,3% resultan severas, lo cual describe una situación previamente desconocida en Colombia.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Rheumatoid arthritis]]></kwd>
<kwd lng="en"><![CDATA[Biological therapy]]></kwd>
<kwd lng="en"><![CDATA[Adverse event]]></kwd>
<kwd lng="en"><![CDATA[Adverse reaction]]></kwd>
<kwd lng="es"><![CDATA[Artritis reumatoide]]></kwd>
<kwd lng="es"><![CDATA[Terapia biológica]]></kwd>
<kwd lng="es"><![CDATA[Evento adverso]]></kwd>
<kwd lng="es"><![CDATA[Reacción adversa]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ortega]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinical practice guide rheumatoid arthritis.]]></source>
<year>2011</year>
<page-range>1-14.</page-range><publisher-name><![CDATA[Essalud Gob Pe]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud (OMS)</collab>
<source><![CDATA[Epidemiology]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Washington ]]></publisher-loc>
<publisher-name><![CDATA[OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Entezami]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Clapham]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Historical perspective on the etiology of rheumatoid arthritis]]></article-title>
<source><![CDATA[Hand Clin.]]></source>
<year>2011</year>
<volume>27</volume>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schett]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Emery]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Burmester]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pisetsky]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Naredo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: Current evidence and future directions]]></article-title>
<source><![CDATA[Ann Rheum Dis.]]></source>
<year>2016</year>
<volume>75</volume>
<page-range>1428-37</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud (OMS)</collab>
<source><![CDATA[Patient safety]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Washington ]]></publisher-loc>
<publisher-name><![CDATA[OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Catay]]></surname>
<given-names><![CDATA[ER,]]></given-names>
</name>
<name>
<surname><![CDATA[Soriano]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento biológico en reumatología]]></article-title>
<source><![CDATA[Rev Hosp Ital B Aires.]]></source>
<year>2014</year>
<volume>34</volume>
<page-range>76-83</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quintana]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Restrepo]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Cáceres]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Rueda]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Rosselli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic evaluation of the treatment of rheumatoid arthritis with anti-TNF biological therapy in Colombia]]></article-title>
<source><![CDATA[Acta Medica Colomb.]]></source>
<year>2011</year>
<volume>36</volume>
<page-range>24-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ogata]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Higa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshizaki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review]]></article-title>
<source><![CDATA[Mod Rheumatol]]></source>
<year>2018</year>
<volume>0</volume>
<page-range>1-29</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández-Ávila]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Rincón-Riaño]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal-Macías]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez Dávila]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Rosselli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of rheumatoid arthritis in Colombia according to information from the Integral Social Protection Information System]]></article-title>
<source><![CDATA[Rev Colomb Reumatol]]></source>
<year>2019</year>
<volume>26</volume>
<page-range>83-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>Gobierno de Colombia</collab>
<source><![CDATA[Abecé de los medicamentos biotecnológicos]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Dirección de Medicamentos y Tecnologías Sanitarias de Colombia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calderón-Ospina]]></surname>
<given-names><![CDATA[CA,]]></given-names>
</name>
<name>
<surname><![CDATA[Urbina-Bonilla]]></surname>
<given-names><![CDATA[ADP.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La farmacovigilancia en los últimos 10 años: actualización de conceptos y clasificaciones Logros y retos para el futuro en Colombia.]]></article-title>
<source><![CDATA[Médicas UIS.]]></source>
<year>2011</year>
<volume>24</volume>
<page-range>53-66</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heidari]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatoid Arthritis: Early diagnosis and treatment outcomes]]></article-title>
<source><![CDATA[Caspian J Intern Med]]></source>
<year>2011</year>
<volume>2</volume>
<page-range>161-70</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blomjous]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Boers]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Den Uyl]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Twisk]]></surname>
<given-names><![CDATA[JWR]]></given-names>
</name>
<name>
<surname><![CDATA[Van Schaardenburg]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Voskuyl]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictors of sick leave and improved worker productivity after 52 weeks of intensive treatment in patients with early rheumatoid arthritis]]></article-title>
<source><![CDATA[Scand J Rheumatol]]></source>
<year>2019</year>
<volume>48</volume>
<page-range>271-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Botero Aguirre]]></surname>
<given-names><![CDATA[JP,]]></given-names>
</name>
<name>
<surname><![CDATA[Restrepo Hamid]]></surname>
<given-names><![CDATA[AM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caracterización de las reacciones adversas a medicamentos reportadas al programa de farmacovigilancia de un hospital de alta complejidad y factores asociados con su evitabilidad.]]></article-title>
<source><![CDATA[Medicina UPB.]]></source>
<year>2013</year>
<volume>32</volume>
<page-range>129-37</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caporali]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Conti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Alivernini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Atzeni]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Seriolo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Cutolo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy]]></article-title>
<source><![CDATA[Clin Exp Rheumatol]]></source>
<year>2011</year>
<volume>29</volume>
<numero>3^s66</numero>
<issue>3^s66</issue>
<supplement>66</supplement>
<page-range>S7-14</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez-Valverde]]></surname>
<given-names><![CDATA[V,]]></given-names>
</name>
<name>
<surname><![CDATA[Cáliz Cáliz]]></surname>
<given-names><![CDATA[R,]]></given-names>
</name>
<name>
<surname><![CDATA[Álvaro-Gracia]]></surname>
<given-names><![CDATA[Álvaro JM]]></given-names>
</name>
<name>
<surname><![CDATA[Marenco de la Fuente]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Mulero Mendoza]]></surname>
<given-names><![CDATA[J,]]></given-names>
</name>
<name>
<surname><![CDATA[Tornero Molina]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[III Actualización del Consenso de la Sociedad Española de Reumatología sobre terapia biológica en la artritis reumatoide.]]></article-title>
<source><![CDATA[Rheumatol Clin.]]></source>
<year>2006</year>
<volume>2</volume>
<page-range>52-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franco Fraguas]]></surname>
<given-names><![CDATA[L,]]></given-names>
</name>
<name>
<surname><![CDATA[Savio]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medicamentos biotecnológicos. Conceptos básicos y relevancia en el contexto clínico.]]></article-title>
<source><![CDATA[Tend Med.]]></source>
<year>2008</year>
<volume>16</volume>
<page-range>5-12</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez-Reino]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Carmona]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Valverde]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Mola]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Montero]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2003</year>
<volume>48</volume>
<page-range>2122-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Wells]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Christensen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tanjong Ghogomu]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Maxwell]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Macdonald]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse effects of biologics: A network meta-analysis and Cochrane overview]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2011</year>
<page-range>CD008794</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[WH,]]></given-names>
</name>
<name>
<surname><![CDATA[Genovese]]></surname>
<given-names><![CDATA[MC,]]></given-names>
</name>
<name>
<surname><![CDATA[Moreland]]></surname>
<given-names><![CDATA[LW.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?]]></article-title>
<source><![CDATA[Arthritis Rheum.]]></source>
<year>2001</year>
<volume>44</volume>
<page-range>1977-83</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molloy]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Calabrese]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2012</year>
<volume>64</volume>
<page-range>3043-51</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leombruno]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Einarson]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Keystone]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure- adjusted pooled analyses of serious adverse events]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2009</year>
<volume>68</volume>
<page-range>1136-45</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perez-Alvarez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Perez-de-Lis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz-Lagares]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pego-Reigosa]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Retamozo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bove]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interstitial lung disease induced or exacerbated by TNF-targeted therapies: Analysis of 122 cases]]></article-title>
<source><![CDATA[Semin Arthritis Rheum]]></source>
<year>2011</year>
<volume>41</volume>
<page-range>256-64</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="book">
<collab>Ministerio de Protección Social</collab>
<source><![CDATA[Seguridad del paciente y cuidado seguro]]></source>
<year>2010</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Protección Social]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
